Overall, this study contributes to our understanding of the biology of nausea and vomiting in pregnancy and may lead to future research evaluating new treatment avenues. Of note, drugs targeting the GDF15 pathway have shown great promise in mitigating weight loss, loss of appetite, and vomiting in animal models and are currently in clinical trials in cancer cachexia, a disease with similar symptoms to HG.
Hyperemesis Gravidarum (HG) is not self-limiting, and its impact can last a lifetime for mothers and their children. Until there is recognition of this fact and comprehensive, universal, effective treatment for all HG patients, every level of society will continue to face the costs of HG.
February is Heart Health Month, and the HER Foundation shares 4 ways for you to protect your heart.
May 15th is International HG Awareness Day. You can help the HER Foundation raise awareness and educate. HG is real. Believe Us!
Dr. Marlena Fejzo, HER Research Adviser and Board of Directors, was invited to speak at February’s Keystone Conference on Maternal-Fetal Crosstalk in Santa Fe, NM. Dr. Fejzo presented “Evidence the placenta and appetite hormone GDF15 causes nausea and vomiting of pregnancy” and met with experts on maternal/fetal health from around the world.
Be a part of finding answers about Hyperemesis Gravidarum (HG). Currently, the HER Foundation has three active research surveys. Please participate!
In 2023, we will continue our support of families across the globe, continue our groundbreaking research, advocate to change policy to improve maternal and fetal outcomes, and launch an exciting new education program!
The HER Foundation has accomplished a lot in 2022! We are thankful for the support of our donors and community and want to share the highlights that made this HER’s best year yet! This is what 22 years of Helping Generations survive Hyperemesis Gravidarum (HG) looks like.

